Immunovant
IMVT · NASDAQ
$28.59+$0.97 (+3.51%)TodayMarket closed ·
Prev close $27.62
EPS: actual vs estimate
Beat the estimate in 2 of the last 8 quarters, by 6.5% on average
Next report: , before the market opens
- Quarter
- Q2 FY27
- EPS estimate
- -$0.72
Reported EPS
Estimated EPS
| Quarter | Estimate | Reported | Surprise |
|---|---|---|---|
| Q2 FY26 | -$0.6277 | -$0.75 | −19.5% |
| Q1 FY27 | -$0.6277 | -$0.75 | −19.5% |
| Q1 FY26 | -$0.6129 | -$0.73 | −19.1% |
| Q4 FY25 | -$0.7309 | -$0.64 | +12.4% |
| Q3 FY25 | -$0.7642 | -$0.76 | +0.5% |
| Q2 FY25 | -$0.609 | -$0.74 | −21.5% |
| Q1 FY25 | -$0.5379 | -$0.60 | −11.5% |
| Q4 FY24 | -$0.4352 | -$0.52 | −19.5% |
Earnings calls
- IMVT - Earnings call Q1 2027
- Special Call - Immunovant, Inc.
- IMVT - Earnings call Q3 2026
- IMVT - Earnings call Q2 2026
- BofA Securities 2025 Healthcare Conference
- Special Call - Immunovant, Inc.
- Special Call - Immunovant, Inc.
- 43rd Annual J.P. Morgan Healthcare Conference 2025
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.